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Abstract
Background: Aprotinin has been shown to be effective in reducing peri-operative blood loss and
the need for re-operation due to continued bleeding in cardiac surgery. The lysine analogues
tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) are cheaper, but it is not known if
they are as effective as aprotinin.
Methods: Studies were identified by searching electronic databases and bibliographies of published
articles. Data from head-to-head trials were pooled using a conventional (Cochrane) meta-analytic
approach and a Bayesian approach which estimated the posterior probability of TXA and EACA
being equivalent to aprotinin; we used as a non-inferiority boundary a 20% increase in the rates of
transfusion or re-operation because of bleeding.
Results:  Peri-operative blood loss was significantly greater with TXA and EACA than with
aprotinin: weighted mean differences were 106 mls (95% CI 37 to 227 mls) and 185 mls (95% CI
134 to 235 mls) respectively. The pooled relative risks (RR) of receiving an allogeneic red blood
cell (RBC) transfusion with TXA and EACA, compared with aprotinin, were 1.08 (95% CI 0.88 to
1.32) and 1.14 (95% CI 0.84 to 1.55) respectively. The equivalent Bayesian posterior mean relative
risks were 1.15 (95% Bayesian Credible Interval [BCI] 0.90 to 1.68) and 1.21 (95% BCI 0.79 to 1.82)
respectively. For transfusion, using a 20% non-inferiority boundary, the posterior probabilities of
TXA and EACA being non-inferior to aprotinin were 0.82 and 0.76 respectively. For re-operation
the Cochrane RR for TXA vs. aprotinin was 0.98 (95% CI 0.51 to 1.88), compared with a posterior
mean Bayesian RR of 0.63 (95% BCI 0.16 to 1.46). The posterior probability of TXA being non-
inferior to aprotinin was 0.92, but this was sensitive to the inclusion of one small trial.
Conclusion: The available data are conflicting regarding the equivalence of lysine analogues and
aprotinin in reducing peri-operative bleeding, transfusion and the need for re-operation. Decisions
are sensitive to the choice of clinical outcome and non-inferiority boundary. The data are an
uncertain basis for replacing aprotinin with the cheaper lysine analogues in clinical practice.
Progress has been hampered by small trials and failure to study clinically relevant outcomes.
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Background
Excessive peri-operative bleeding during cardiac surgery
involving cardiopulmonary bypass contributes to overall
morbidity and mortality [1-6]. Blood loss frequently leads
to transfusion of allogeneic blood products, which expose
patients to the risk of transfusion-related adverse effects
such as febrile non-hemolytic transfusion reactions, trans-
fusion errors and blood-borne infections [2,7]. Concerns
about blood safety, continual blood shortages and rising
costs of blood bank operations have generated interest in
the reduction of transfusion requirements during and
after surgery. A popular approach is to minimize peri-
operative bleeding through the prophylactic use of the
antifibrinolytic agents aprotinin, tranexamic acid (TXA),
and epsilon aminocaproic acid (EACA) [8].
Aprotinin, the benchmark compound, is the most widely
used and best established antifibrinolytic medication. It is
a non-specific broad-spectrum serine protease inhibitor
mainly derived from bovine lungs [9]. TXA and EACA are
synthetic lysine analogues, which act principally by block-
ing lysine binding sites on plasminogen molecules, inhib-
iting plasmin formation and thereby fibrinolysis [10].
Several published systematic reviews have shown apro-
tinin to be efficacious in reducing peri-operative blood
loss, patient exposure to allogeneic blood transfusion and
the need for re-operation due to continued or recurrent
bleeding [1,2,11-13]. TXA and EACA also have demon-
strated efficacy in placebo-controlled trials [1,2,12,13],
but the available literature does not allow conclusions to
be drawn about the comparative clinical performance of
these agents. It is important to establish the relative per-
formance of these agents as aprotinin is substantially
more expensive than either TXA or EACA.
In synthesizing the available literature we were interested
in whether TXA and EACA are as effective (i.e. no worse
than) as the more expensive drug, aprotinin. To achieve
this aim we performed a meta-analysis of data obtained
from head-to-head randomized controlled trials of apro-
tinin, TXA, and EACA and performed tests of equivalence
(non-inferiority) using a Bayesian approach.
Methods
Search strategy
This systematic review was undertaken using the methods
established by the Cochrane Collaboration [14]. Data-
bases searched were: Medline (1966–September 2003),
EMBASE (1980–September 2003), Current Contents
(1993–Week 34 2003) and the Cochrane Central Register
of Controlled Trials (CENTRAL – The Cochrane Library,
Issue 2, 2003). Initially we used unrestricted search strate-
gies, employing exploded MeSH (Medical Subject Head-
ings) terms and specific text-word terms for aprotinin,
tranexamic acid, and epsilon aminocaproic acid. The spe-
cific text-word terms included: 'aprotinin', 'antilysin',
'contrical', 'kallikrein-trypsin', 'kallikrein inhibitor$', 'kal-
likrein inactivator$', 'tranexamic acid', 'cyklokapron', 't-
amcha', 'amca', 'amcha', urugol', 'transamin', 'kabi', 'exa-
cyl', 'anvitoff', 'epsilon aminocaproic acid', 'amicar', and
'lederle'. The truncation character "$" was used in Medline
and EMBASE to retrieve all possible suffix variations of the
root word or phrase. In Medline, EMBASE (Excerpta Med-
ica Database), and Current Contents two search filters
were used to restrict and improve the specificity of the
electronic database searches. Firstly, the ISPOT (Interna-
tional Study of Peri-operative Transfusion) filter [11]
which identifies blood transfusion trials, and secondly, a
modified version of the Cochrane Collaboration filter
[15], which identifies randomized controlled trials. These
search filters were combined with the MeSH and relevant
text-word terms for aprotinin, TXA, and EACA. Experts in
the field were contacted to identify relevant reports or
projects in progress relevant to the review. The bibliogra-
phies of identified trials, review articles, and reports were
searched for potentially relevant studies. Studies were
retrieved regardless of language.
Study selection criteria
Two reviewers (PAC and AJM) independently evaluated
identified articles for eligibility. Studies were eligible for
inclusion if they were randomized parallel-group trials,
evaluated the drugs as prophylactic interventions in the
context of adult elective cardiac surgery, involved the
intravenous administration of the trial agents during the
pre and/or intra-operative period, and included in their
study outcomes the numbers of individuals who received
allogeneic RBC transfusions, or the volume of allogeneic
RBCs received by subjects in the intervention groups.
Duplicate publications, studies involving only children
(less than 18 years), and trials that only administered the
study drugs during the post-operative period were not
considered for review.
Data extraction
The outcomes measured included: the numbers of
patients exposed to allogeneic red blood cell transfusion,
and/or the amounts of allogeneic RBC transfused
(expressed as units), blood loss (expressed as milliliters),
the rates of re-operation for bleeding (re-exploration),
non-fatal myocardial infarction, stroke, thrombosis, and
mortality. Data were extracted from each trial by two
reviewers (PAC and AJM), checked for consistency and
accuracy, and then entered into a computer database for
analysis.
Data analysis
Dichotomous data (e.g. required re-operation for bleed-
ing or numbers of patients who were transfused) andBMC Cardiovascular Disorders 2005, 5:19 http://www.biomedcentral.com/1471-2261/5/19
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continuous data (e.g. mean volume of blood loss and
mean units of allogeneic RBC transfused) were analyzed
using Cochrane Review Manager 4.1 (MetaView 4.1) [16].
Trials were excluded from analysis if they did not report
conventional measures of dispersion (standard deviations
or standard errors) along with means for continuous data
(or if we were unable to calculate these from the raw data).
Data expressed in milliliters (mls) of blood transfused
were converted to units by dividing by 300. Outcomes are
expressed as pooled relative risks (RR) or weighted mean
differences (WMD) (for continuous variables) using a ran-
dom effects model [17]. The Q statistic was used to assess
heterogeneity of treatment effect [17]. We also used a
Bayesian approach (utilizing WinBUGS software) to
model the results of the individual trials as a binomial
experiment. We employed a random effects model to cal-
culate the pooled risk ratio, using the methods described
by Warn et al.[18]. We used a Uniform (0,1) prior for the
risk of allogeneic RBC transfusion with aprotinin treat-
ment (consistent with the reported 50% transfusion rate
in cardiac surgery) and estimated a prior for re-operation
rates with aprotinin from the results of a published sys-
tematic review [12]. We integrated the posterior distribu-
tion curve for the RR between various pairs of limits to
summarize the probabilities of interest. In doing this we
were indifferent to the probability of superiority of lysine
analogues over aprotinin, but included those areas of the
curves in the calculation of the probabilities of non-infe-
riority. We selected a non-inferiority boundary of 20%
(delta value) for re-operation data and the rate of transfu-
sion with allogeneic blood (i.e. TXA & EACA were consid-
ered non-inferior to aprotinin if the upper limit of the
95% CI for the pooled RR was ≤1.2). The delta value was
varied during sensitivity analysis (i.e. 5% to 40%).
Assessment of study methodological quality
Studies were assessed for methodological quality by two
independent raters (PAC and AJM), using criteria pro-
posed by Schulz et al.[19]. These specify four items of
assessment: double-blinding, allocation concealment,
participant inclusion/exclusion and methods used to
achieve randomization. Disagreements were resolved by
consensus. Inter-rater agreement for each item of method-
ological quality was assessed by comparing the observed
agreement with that expected by chance. A kappa statistic
(which expresses the agreement beyond chance as a pro-
portion of the maximum possible agreement) was calcu-
lated for each item assessed. Kappa is equal to one when
there is perfect agreement between raters.
Results
We identified twenty randomized, head-to-head trials
involving comparisons of aprotinin TXA and EACA in
elective adult cardiac surgery, which reported information
on the main outcomes of interest [6,20-38]. One trial [39]
was excluded from the analysis due to a lack of usable data
(i.e. for continuous data the results were reported as medi-
ans [25th–75th percentiles]; the number of patients trans-
fused  ≥1 unit of allogeneic RBC transfusion was not
reported).
Characteristics of included studies
The 20 included trials (Tables 1 &2) randomized a total of
2430 subjects to receive either aprotinin, TXA, or EACA.
The majority (n = 11) compared aprotinin to TXA. There
were only three head-to-head trials of aprotinin versus
EACA, three trials of TXA versus EACA, and three trials
that compared the three antifibrinolytic drugs with each
other. The median size of trial arms was 25 participants
(range; 14–522). For each of the three intervention groups
the mean age of study participants ranged from 60.5–62.4
years. Most study participants were male (77–79%). The
publication period of the trials spanned nine years (1993
to 2001). Only one trial was published in a language other
than English and was translated before being included in
the analysis [23]. The trials were heterogeneous in terms
of drug dose and treatment regimen (Table 3).
Methodological quality of the studies
Nineteen of the 20 trials were assessed for methodological
quality by the two raters (PAC and AJM). As the non-Eng-
lish language study [23] could not be adequately assessed
by the two raters, it was excluded from the analysis of the
reliability of quality assessment procedure. For the four
items of the Schulz criteria [19] used to assess trial quality,
the observed agreement was good with kappa scores rang-
ing from 0.92 to 1.0. Generally, the methodological qual-
ity of the trials reviewed was poor. Double-blinding was
reported in eight trials (42%), concealment of treatment
allocation was judged to be adequate in four trials (21%),
and only four trials (21%) described the method used to
generate allocation sequences (i.e. randomization proce-
dure). Follow-up was judged to have been complete in
five trials (26%). For seven trials there was incomplete fol-
low-up; however for these trials only a small number of
exclusions were reported making differential withdrawal
an unlikely source of bias. For the seven remaining trials a
rationale for the withdrawal of study subjects was not pro-
vided. As the majority of trials were of poor methodolog-
ical quality stratification of the data by methodological
quality and subgroup analyses were uninformative. We
were therefore unable to determine whether treatment
effect estimates varied due to study methodological
quality.
Meta-analyses
TXA vs. Aprotinin (10 trials, 1707 subjects)
On average, TXA was inferior to aprotinin in reducing 24
hour blood loss (WMD 106 mls, 95% CI 37 to 176 mls;
Fig 1). This apparent disadvantage of TXA was notBMC Cardiovascular Disorders 2005, 5:19 http://www.biomedcentral.com/1471-2261/5/19
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reflected in the transfusion data. For the five trials (N =
357 subjects) that reported on the amount of blood trans-
fused, the mean numbers of red cell units did not differ
between the two drugs; WMD 0.06 units (95% CI -0.18 to
0.31 units). The rate of red cell transfusion in patients
treated with TXA was 37.2% compared with 36.5% with
aprotinin (Cochrane RR 1.08, 95% CI 0.88 to 1.32; Fig 2).
The equivalent Bayesian posterior mean relative risk was
1.11 (95% BCI 0.92 to 1.45). Data on re-operation rates
were sparse (Fig 3). The Cochrane estimate of the pooled
RR for re-operation with TXA compared to aprotinin was
close to one (RR 0.98, 95% CI 0.51 to 1.88). In contrast,
the Bayesian posterior mean risk ratio was 0.63 (95% BCI
0.16 to 1.46). Most of the difference between TXA and
aprotinin seemed to be contributed by one study (Nuttall
et al.[32]). This study reported re-operation rates of 0/45
with tranexamic acid and 6/45 with aprotinin, equating to
an absolute risk reduction of 13% [risk difference (RD) -
0.13, 95% CI -0.24 to -0.03]. In comparison, none of the
remaining trials reached statistical significance for this
outcome with the risk differences ranging from -0.03 to
0.07 and the 95% confidence intervals including unity
(RD = 0). Excluding the data from this one trial [32]
changed the mean posterior RR to 0.93 (95% BCI 0.30 to
1.96).
For RBC transfusion the estimated posterior probability of
non-inferiority TXA to aprotinin (with a pooled RR
threshold of 1.2) was 0.82. If the threshold was set to 1.1
the posterior probability of non-inferiority was 0.57 (Fig
4). The probabilities of non-inferiority of TXA for re-oper-
ation were higher than for transfusion, being 0.92 and
0.90 for the delta values of 20% and 10% respectively, but
fell to 0.69 and 0.64 when the data from Nuttall et al.[32]
were excluded from the calculations.
EACA vs. Aprotinin (6 trials; 399 subjects)
EACA was inferior to aprotinin in controlling blood loss
over 24 hours (WMD 184 mls, 95% CI 134 to 235 mls; Fig
5). However, the mean number of units of allogeneic RBC
transfused did not differ between the drugs (WMD -0.22
units, 95% CI -0.52 to 0.09 units). Transfusion rates were
similar for EACA and aprotinin: Cochrane RR 1.14 (95%
CI 0.84 to 1.55); Bayesian posterior mean risk ratio 1.08
(95% BCI 0.73 to 1.52). Using a non-inferiority threshold
value of 1.2 for the pooled RR, the probability of EACA
being non-inferior to aprotinin was 0.76. With the
Table 1: Characteristics of Included Studies
Study Year Country Type of cardiac surgery Interventions
Isetta et al. [25] 1993 France NR HD APR (n = 70) vs. LD APR (n = 70) vs. TXA (n = 70) 
vs. Control (n = 70)
Blauhut et al. [27] 1994 Switzerland CABG HD APR (n = 14) vs. TXA (n = 14) vs. Control (n = 14)
Penta de Peppo et al. [20] 1995 Italy CABG & Valve Sx. HD APR (n = 15) vs. TXA (n = 15) vs. EACA (n = 15) vs. 
Control (n = 15)
Corbeau et al. [23] 1995 France CABG & Valve Sx. HD APR (n = 43) vs. TXA (n = 41) vs. Control (n = 20)
Pugh et al. [22] 1995 UK Primary CABG LD APR (n = 21) vs. TXA (n = 22) vs. Control (n = 23)
Speekenbrink et al. [21] 1995 The Netherlands Primary CABG PP APR (n = 15) vs. TXA (n = 15) vs. DIP (n = 12) vs. 
Control (n = 15)
Menichetti et al. [24] 1996 Italy Primary CABG HD APR (n = 24) vs. TXA (n = 24) vs. EACA (n = 24) vs. 
Control (n = 24)
Pinosky et al. [33] 1997 USA Primary CABG TXA (n = 20) vs. EACA (n = 20) vs. Placebo (n = 19)
Mongan et al. [31] 1998 USA Primary CABG HD APR (n = 75) vs. TXA (n = 75)
Hardy et al. [26] 1998 Canada Primary CABG TXA (n = 42) vs. EACA (n = 46) vs. Placebo (n = 44)
Eberle et al. [29] 1998 Germany Primary CABG HD APR (n = 20) vs. EACA (n = 20)
Misfeld et al. [30] 1998 Germany Primary CABG LD APR (n = 14) vs. TXA (n = 14) vs. Control (n = 14)
Casati et al. [28] 1999 Italy Primary CABG & Valve Sx. HD APR (n = 67) vs. TXA (n = 70) vs. EACA (n = 66)
Bernet et al. [34] 1999 Switzerland Primary CABG HD APR (n = 28) vs. TXA (n = 28)
Nuttall et al. [32] 2000 USA Re-do CABG & Valve Sx. HD APR (n = 40) vs. TXA (n = 45) vs. TXA+ANH (n = 
32) vs Placebo (n = 43)
Maineri et al. [38] 2000 Italy Primary CABG TXA (n = 24) vs. EACA (n = 24)
Wong et al. [37] 2000 Canada Re-do CABG & Valve Sx. HD APR (n = 39) vs. TXA (n = 38)
Casati et al. [35] 2000 Italy Primary CABG & Valve & 
ASD Repair
HD APR (n = 518) vs. TXA (n = 522)
Greilich et al. [36] 2001 USA Primary CABG HD APR (n = 24) vs. EACA (n = 23) vs. Placebo (n = 25)
Ray et al. [6] 2001 Australia CABG & Valve Sx. LD APR (n = 49) vs. EACA (n = 51)
ANH = acute normovolemic hemodilution, APR = aprotinin, ASD = atrial septal defect, CABG = coronary artery bypass graft, DIP = dipyridamole, 
EACA = epsilon aminocaproic acid, HD = high dose, LD = low dose, NR = not reported, PP = pump prime, Sx. = surgery, TXA = tranexamic acidBMC Cardiovascular Disorders 2005, 5:19 http://www.biomedcentral.com/1471-2261/5/19
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threshold set at 1.1 the posterior probability of non-infe-
riority dropped to 0.54 (Fig 6). There were insufficient
data to analyze the effects of treatment on re-operation
rates.
Other outcomes
Analyses of other clinical outcomes such as all cause mor-
tality, myocardial infarction and stroke were generally
uninformative because of the sparse data, but we saw no
trends favoring any of the drugs studied here, compared
with the others (data not displayed).
Table 2: Characteristics of Included Studies
Study Co-interventions Transfusion threshold Anti-platelet use
Isetta et al. [25] PO CS - re-transfusion of SMB Hct<20% during CPB
Hct<25% 4 hrs post CPB
Hct<27% post-op.
NR
Blauhut et al. [27] NR Hct<30% post-op. Excluded pts. pre-operatively treated with 
ASA + NSAIDs
Penta de Peppo et al. [20] IO CS + IO & PO re-transfusion of 
SMB
Post-op. non-monitored pts. 
Hb<7.0 g/dL
Monitored pts. Hb<8.5 g/dL
Discontinued NSAIDs 24 hrs before Sx.
Corbeau et al. [23] NR Hct<20% during CPB
Hct<25% at the end of surgery
Hct<30 post extubation
Anti-platelet aggregation drugs ceased 10 
days pre-operatively
Pugh et al. [22] IO CS + ANH (1 unit of WB 
collected pre-CPB then re-
transfused post CPB)
Hct<20% during CPB
Hct<30% off CPB
Aspirin use within 10 days of the operation: 
LD APR = 67%, TXA = 91%, Control = 78%
Speekenbrink et al. [21] NR NR Aspirin discontinued 2–4 days before Sx.
Menichetti et al. [24] NR Hct<30% post-operatively Excluded pts. who had taken ASA or DIP 
until 2 weeks pre-op.
Pinosky et al. [33] NR Hct<20% + surgeon preference Pre-operative aspirin use: TXA = 25%, 
EACA = 40%, Placebo = 42%
Mongan et al. [31] NR Hb<6.0 g/dL during CPB
Hb<8.0 g/dL off CPB
Pre-operative aspirin use: HD APR = 44%, 
TXA = 53%
Hardy et al. [26] IO CS & Re-infusion of SMB were 
not used
Hb<7.0 g/dL during CPB
Hb<8.0 g/dL off CPB
NR
Eberle et al. [29] IO & PO CS used Hct<27% - post-operative + 
accompanied by signs & symptoms 
of hypovolemia
Intra-operative IV ASA: HD APR = 5.0%, 
EACA = 15%
Misfeld et al. [30] NR Hb<8.0 g/dL Excluded pts. receiving ASA treatment 
within 5 days of Sx.
Casati et al. [28] IO CS used + PAD Hb<6.0 g/dL during CPB
Hb<8.0 g/dL off CPB + clinical 
condition
Pts. receiving ASA treatment within 5 days 
of Sx.: HD APR = 37.8%, TXA = 40.9%, 
EACA = 35.3%
Bernet et al. [34] PO CS Hct<25% PO All pts. were treated with 100 mg ASA daily 
until Sx.
Nuttall et al. [32] PAD not used Hb<7.0 g/dL during CPB Excluded pts. taking ASA daily (≥325 mg) 
before Sx.
Maineri et al. [38] IO CS + PO re-infusion of SMB Hct<30% IO
Hct<28% PO
NR
Wong et al. [37] IO CS + PO re-infusion of SMB Hb<7.0 g/dL IO
Hb<8.0 g/dL PO
Excluded pts. receiving ASA treatment 
within 5 days of Sx.
Casati et al. [35] IO CS used Hb<6.0 g/dL during CPB
Hb<8.0 g/dL PO
Pts. receiving ASA treatment before Sx.: 
HD APR = 17.8%, TXA = 18.8%
Greilich et al. [36] IO CS used PO SMB was not used Hb<8.0 g/dL Pts. receiving ASA treatment before Sx.: 
HD APR = 88%, EACA = 90%, Placebo = 
79%
Ray et al.  [ 6 ] N RN RA S A  w i t h i n  1 0  d a ys before Sx.: LD APR = 
22.4%, EACA = 33.3%
ANH = acute normovolemic hemodilution, APR = aprotinin, ASA = acetylsalicylic acid, CABG = coronary artery bypass graft, CPB = 
cardiopulmonary bypass, CS = cell salvage, DIP = dipyridamole, EACA = epsilon aminocaproic acid, Hb = hemoglobin, Hct = hematocrit, HD = high 
dose, LD = low dose, NR = not reported, NSAIDs = non-steroidal anti-inflammatory drugs, PP = pump prime, IO = intra-operative, PO = post-
operative, SMB = shed mediastinal blood, Sx. = surgery, TXA = tranexamic acid, WB = whole bloodBMC Cardiovascular Disorders 2005, 5:19 http://www.biomedcentral.com/1471-2261/5/19
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Table 3: Summary of drug dose and treatment regimens
Study Aprotinin TXA EACA
Isetta et al. [25] L = 2.0 × 106 KIU
M = 0.5 × 106 KIU/h
P = 2.0 × 106 KIU
L = 15 mg/kg NS
L = 0.5 × 106
M = 0.5 × 106
Blauhut et al. [27] L = 2.0 × 106 KIU
M = 0.5 × 106 KIU/h
P = 1.0 × 106 KIU
L = 10 mg/kg
M = 1.0 mg/kg/h
NS
Penta de Peppo et al. [20] L = 2.0 × 106 KIU
M = 0.5 × 106 KIU/h
P = 2.0 × 106 KIU
L = 10 mg/kg M = 1.0 mg/kg/h L = 10 g
M = 2.0 g/h for 5 h
Corbeau et al. [23] L = 2.0 × 106 KIU
M = 0.5 × 106 KIU/h
P = 2.0 × 106 KIU
L = 15 mg/kg
E = 15 mg/kg
NS
Pugh et al. [22] L = 1.0 × 106 KIU
P = 1.0 × 106 KIU
L = 2.5 g
P = 2.5 g
NS
Speekenbrink et al. [21] P = 2.0 × 106 KIU L = 10 mg/kg
M = 1.0 mg/kg/h
NS
Menichetti et al. [24] L = 2.0 × 106 KIU
M = 0.5 × 106 KIU/h
P = 2.0 × 106 KIU
L = 10 mg/kg
M = 3.0 mg/kg/h
P = 10 mg/kg
L = 80 mg
M= 30 mg/kg/h
P = 80 mg/kg
Pinosky et al. [33] NS L = 15 mg/kg
M = 1.0 mg/kg/h for 6 h
L = 150 mg/kg
M = 10 mg/kg/h for 6 h
Mongan et al. [31] L = 2.0 x 106 KIU
M = 0.5 × 106 KIU/h
P = 2.0 × 106 KIU
L = 15 mg/kg
M = 2.0 mg/kg/h for 6 h
NS
Hardy et al. [26] NS L = 10 g L = 15 g
M = 1.0 g/h
Eberl et al. [29] L = 2.0 × 106 KIU
M = 0.5 × 106 KIU/h
P = 2.0 × 106 KIU
NS L = 10 g
M = 2.5 g/h
P = 10 g
Misfeld et al. [30] P = 1.0 × 106 KIU
E = 0.2 × 106 KIU/h for 5 h
L = 10 mg/kg
M = 1.0 mg/kg/h
NS
Casati et al. [28] L = 2.0 × 106 KIU
M = 0.5 × 106 KIU/h
P = 2.0 × 106 KIU
L = 1.0 g
M = 400 mg/h
P = 500 mg
L = 5.0 g
M = 2.0 g/h
P = 2.5 g
Bernet et al. [34] L = 2.0 × 106 KIU
M = 0.5 × 106 KIU/h
P = 2.0 × 106 KIU
L = 10 g NS
Nuttall et al. [32] L = 2.0 × 106 KIU
M = 0.5 × 106 KIU/h
P = 2.0 × 106 KIU
L = 10 mg/kg
M = 1.0 mg/kg/h
NS
Maineri et al. [38] NS L = 20 mg/kg
M = 2.0 mg/kg/h
L = 10 g
M = 2.0 g/h
Wong et al. [37] L = 2.0 × 106 KIU
M = 0.5 × 106 KIU/h
P = 2.0 × 106 KIU
L = 10 g NS
Casati et al. [35] L = 2.0 × 106 KIU
M = 0.5 × 106 KIU/h
P = 2.0 × 106 KIU
L = 1.0 g
M = 400 mg/h
P = 500 mg
NS
Greilich et al. [36] L = 2.0 × 106 KIU
M = 0.5 × 106 KIU/h
P = 2.0 × 106 KIU
NS L = 100 mg/kg
M = 2.5 mg/kg/h
P = 5.0 g
Ray et al. [6] L = 1.0 × 106 KIU
P = 1.0 × 106 KIU
NS L = 5.0 g
M = 1.25 g/h
P = 5.0 g
L = loading dose, M = maintenance dose/continuous infusion, P = pump prime dose, E = after protamine administration, KIU = kallikrein inhibitor 
units, NS = not studied, mg = milligram, g = gram, kg = kilogram, h = hourBMC Cardiovascular Disorders 2005, 5:19 http://www.biomedcentral.com/1471-2261/5/19
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Forest plot of 10 comparative trials of TXA and aprotinin – weighted mean difference in blood loss Figure 1
Forest plot of 10 comparative trials of TXA and aprotinin – weighted mean difference in blood loss.
Forest plot of 10 comparative trials of TXA and aprotinin – pooled relative risk of requiring an allogeneic red cell transfusion Figure 2
Forest plot of 10 comparative trials of TXA and aprotinin – pooled relative risk of requiring an allogeneic red cell transfusion.BMC Cardiovascular Disorders 2005, 5:19 http://www.biomedcentral.com/1471-2261/5/19
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Direct comparisons between TXA and EACA revealed no
clinically meaningful or significant differences therefore
we did not perform non-inferiority tests for these two
agents.
Discussion
Aprotinin has become a widely used adjunct in cardiac
surgery [2], a practice that is supported by the results of a
large number of placebo-controlled trials [1,11,12]. These
trials have demonstrated reductions in allogeneic red cell
transfusion, and the need for re-operation due to bleed-
ing. Placebo-controlled trials of tranexamic acid (TXA)
and epsilon aminocaproic acid (EACA) have also demon-
strated efficacy, but the data are sparse and it is unclear
from the published indirect comparisons whether they are
as effective as aprotinin [11,12]. This is not an academic
question as both agents are substantially cheaper than
aprotinin. For example, an average course of treatment
with aprotinin in Canada costs CAN$1000, compared
with CAN$100-275 for TXA and approximately CAN$50
for EACA [37].
So there are financial pressures to switch from aprotinin
to the synthetic lysine analogues. But this should only be
contemplated if there is a high degree of confidence that
the treatments are clinically equivalent. Conventional
meta-analysis provides pooled estimates of differences
between treatments (with uncertainty reflected in the
width of the confidence intervals). But to demonstrate an
acceptable level of 'equivalence' we need to estimate and
interpret the probability of a drug's efficacy lying within a
'non-inferiority' boundary [40]. We have to make a judg-
ment about what level of non-inferiority is acceptable,
and agree on a tolerable probability of breaching this
threshold. These are difficult judgments and we accept
that our approach is somewhat arbitrary.
In this paper we used the rates of blood loss, transfusion
with allogeneic red cells and re-operation due to
continued or recurrent bleeding as the outcome variables.
Adequate mortality and morbidity data were not available
from the trials. Both lysine analogues seemed inferior to
aprotinin in controlling peri-operative blood loss, but the
increments were small (between 100 and 200 mls), and of
uncertain clinical significance. In the case of red cell trans-
fusions we set the non-inferiority boundaries at 1.2 (a rel-
ative 20% increase) in the base case analyses. The rate of
transfusion for aprotinin-treated patients in these trials
was around 35%, therefore a non-inferiority threshold of
1.2 translates into an absolute increase of around 6.9% in
transfusion frequency in this population. In the case of
TXA the probability of non-inferiority with this threshold
was 0.82, but was slightly lower in the case of EACA (0.76)
because of sparse data. To achieve a higher level of confi-
dence in the 'equivalence' of TXA, for example 90%, it is
necessary to tolerate a non-inferiority boundary of 1.4 –
an absolute increase in the transfusion rate of around
Forest plot of 9 comparative trials of TXA and aprotinin – pooled relative risk of needing re-operation for bleeding Figure 3
Forest plot of 9 comparative trials of TXA and aprotinin – pooled relative risk of needing re-operation for bleeding.BMC Cardiovascular Disorders 2005, 5:19 http://www.biomedcentral.com/1471-2261/5/19
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12%. It is difficult to know how this will be viewed by cli-
nicians, but some may consider it as an unsatisfactory
basis for switching from a drug of proven efficacy.
As blood transfusion is a practice variable, as opposed to
a clinical end-point variable, it requires a degree of subjec-
tivity on the part of clinicians. The decision to transfuse is
complex and sometimes arbitrary. It will be influenced by
local transfusion protocols, the patient's pre-operative
hemoglobin (Hb), the estimated degree of blood loss and
the presence of co-morbidity (particularly coronary
disease). We do not think that such decisions are likely to
be sensitive to the modest differences in blood loss
reviewed here, in fact that is what the data indicate.
Our analyses encouraged us to have greater confidence in
the equivalence of TXA to aprotinin in preventing the
need for re-operation than the need for transfusion. But
we remain uncertain about these data. For re-operation,
with the threshold for the pooled RR set at 1.2, the prob-
ability of TXA being non-inferior to aprotinin was 0.92.
This is moderately higher than the probability of 0.82 for
RBC transfusion. This is because the Bayesian estimate for
the posterior mean RR was 0.63, with a high proportion
of the posterior probability distribution below a value of
1.0. Consequently, the integrated area below the non-
inferiority boundary of 1.2 was high. Re-operation was
uncommon in this population, being required by only
2.5% of aprotinin recipients. Although the point
estimates of the RR suggested a trend in favor of TXA (not
seen for other outcomes), the confidence intervals were
wide and the results changed (unfavorably for TXA) when
a single small trial (Nuttall et al.[32]), which contributed
disproportionately to the difference between the drugs,
was excluded from calculation. In addition, these trends
are not paralleled by improvements in blood loss (which
was worse with TXA than with aprotinin) or transfusion
requirements. For these reasons we think that the findings
should be interpreted cautiously.
Heterogeneity in trial outcomes was not particularly
prominent in our analyses. For the main study outcome
Posterior probability of TXA being considered non-inferior to aprotinin at different delta values (transfusion data) Figure 4
Posterior probability of TXA being considered non-inferior to aprotinin at different delta values (transfusion data).
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(i.e. number of patients transfused allogeneic blood)
heterogeneity was not statistically significant (TXA vs.
aprotinin, p = 0.13; EACA vs. aprotinin p = 0.55).
Although the results for blood loss indicated statistically
significant heterogeneity (TXA vs. aprotinin, p = 0.0005)
it appears that the data from one trial contributed to this
result (Menichetti et al., 1996). When the data from this
trial were removed from the analysis heterogeneity was no
longer significant (p = 0.29).
We were unable to formally assess the impact that the use
of anti-platelet agents had on treatment effect estimates as
the majority of trials either excluded patients that had
been treated with acetylsalicyclic acid (ASA) or dipyrida-
mole (DIP) within 5–10 days of surgery or discontinued
treatment with these agents pre-operatively to avoid exces-
sive bleeding. However, in those trials that included ASA
or DIP treated patients generally treatment with these
agents was evenly distributed across trial arms.
Stratification of trial data by the use of cell salvage proved
only marginally informative. Subgroup analysis indicated
that for the six trials that used cell salvage the pooled rel-
ative risk of receiving an allogeneic RBC transfusion in
those patients treated with TXA was 0.97 (95%CI 0.84 to
1.12) compared to 1.54 (95%CI 0.82 to 2.91) for the four
studies that did not report the use of cell salvage.
Although there appeared to be a trend toward a reduced
risk of transfusion in those trials that used cell salvage
both results failed to reach statistical significance with the
95% confidence intervals crossing unity. For EACA
subgroup analysis was uninformative due to the small
number of trials.
Conclusion
The conclusions that can be drawn from these data are
limited for a number of other reasons. The studies were of
generally poor quality. This is regrettable as trials of drugs
are generally easier to conduct well than trials of different
transfusion thresholds or surgical techniques. We have
Posterior probability of EACA being considered non-inferior to aprotinin at different delta values (transfusion data) Figure 6
Posterior probability of EACA being considered non-inferior to aprotinin at different delta values (transfusion data).
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not examined the data for publication bias and are uncer-
tain what effect this might have as the trial comparisons
involved active treatments. We have not explored hetero-
geneity in detail, but it was not particularly prominent in
these analyses. The main limitation was the small size of
the trials and the reliance on transfusion rates rather than
more clinically meaningful endpoints. Doubts about the
clinical performance of a treatment are tolerable when the
clinical consequences are slight. However, when the result
of treatment failure is an unplanned visit to the operating
theatre and a further sternotomy or thoracotomy to deal
with the source of continued bleeding we need assurance
about the equivalence of our treatment choices. In our
view the data reviewed here do not provide this reassur-
ance and larger comparative studies using clinically
important endpoints are necessary.
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